Can PALB2 Breast Cancer Patients Access PARP Inhibitors?

Communities›In Treatment For Breast Cancer›Can PALB2 Breast Cancer Patients Access PARP Inhibitors?

VF

Community Member

9 months ago

Does anyone else have high risk early stage breast cancer, the PALB2 gene mutation, but unable to get a PARP inhibitor because insurance only pays if you have the BRCA mutation? They have the exact same mechanism, but no large clinical studies have addressed this, because the population is so small compared to people with the BRCA mutation. PARPs have been shown to work for PALB2 mutated cancers at 85% response rates, where CDK 4/6 treatments fail.

1

1 comment

Comment

Accepted Answer

This insurance coverage challenge with PALB2 mutations and PARP inhibitors is unfortunately common, as coverage policies often lag behind emerging research. Many patients with rarer genetic mutations face similar barriers when treatments haven't been studied in large clinical trials specific to their mutation. Consider discussing with your oncologist about potential appeals processes, patient assistance programs, or clinical trials that might provide access to PARP inhibitors for PALB2-positive breast cancer.

3+ patients found this helpful

CA

Community Member

5 months ago

This insurance coverage challenge with PALB2 mutations and PARP inhibitors is unfortunately common, as coverage policies often lag behind emerging research. Many patients with rarer genetic mutations face similar barriers when treatments haven't been studied in large clinical trials specific to their mutation. Consider discussing with your oncologist about potential appeals processes, patient assistance programs, or clinical trials that might provide access to PARP inhibitors for PALB2-positive breast cancer.

Can PALB2 Breast Cancer Patients Access PARP Inhibitors?

Related Questions